Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Freddie Bray, Mathieu Laversanne, Hyuna Sung et al. · CA A Cancer Journal for Clinicians · 2024 · 23.1K citations · Full text

Medicine, Oncology, Cancer Control +16

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al. · New England Journal of Medicine · 2018 · 3.8K citations · Full text

Medicine, Oncology, Pharmacology +16

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares, Alexander Luft, David Vicente et al. · New England Journal of Medicine · 2018 · 3.6K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

EORTC QLQ-C30 Scoring Manual

Peter Fayers, Neil K. Aaronson, Kristin Bjordal et al. · Research at the University of Copenhagen (University of Copenhagen) · 1995 · 2.4K citations

Education, Biostatistics, Norm-referenced Assessment +2